Drug intelligence / Profile preview

OLOMAX

Development stage: Phase 4
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

OLOMAX is a fixed-dose combination drug developed by Daewoong Pharmaceutical Co. LTD. It contains Olmesartan Medoxomil, Amlodipine Besylate, and Rosuvastatin Ca, and is indicated for the treatment of hypertension and dyslipidemia, particularly in patients with low-intermediate risk for cardiovascular disease. It is administered orally as tablets.

Brand names: OLOMAX
Other names: amlodipine/olmesartan/rosuvastatinamlodipine besylate/olmersartan medoxomil/rosuvastatin calciumolmersartan medoxomil/amlodipine besilate/rosuvastatin calciumolmesartan/amlodipine/rosuvastatin

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on OLOMAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OLOMAX.

Explore the full profile